Rare heterozygous PCSK1 variants in human obesity: the contribution of the p.Y181H variant and a literature review
Using the strategies above, Scripius and its health plan partners achieved a year-over-year growth rate in GLP-1 utilization of 18% in 2023.6 Curbing utilization growth in the GLP-1 category will be one key strategy for health plan payers to keep plan costs and premiums as low as possible
Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies
Primary endpoint in expanded populations and high-risk subgroups Semaglutide versus sitagliptin Among patients with obesity and type 2 diabetes at low, moderate or high cardiovascular risk in clinical practice, the 1-year risk of the composite endpoint of myocardial infarction or stroke was 1.5% (95% CI 1.4% to 1.6%) with semaglutide compared to 1.7% (95% CI 1.6% to 1.9%) with sitagliptin
Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I
FOR HAVE BEEN APPROVED FOR WEIGHT LOSS SOURCE: Medline Plus
